Previous close | 111.65 |
Open | 111.85 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 110.80 - 111.93 |
52-week range | 93.36 - 130.70 |
Volume | |
Avg. volume | 60,728 |
Market cap | 194.377B |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | 28.51 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.04 (1.85%) |
Ex-dividend date | 12 Jan 2023 |
1y target est | N/A |
They don't offer the highest yields, but these strongly profitable businesses are poised to raise their payouts at a blistering pace.
It's that time of year when Wall Street analysts start adjusting their predictions, and one dividend-paying stock, in particular, is getting a lot of positive attention. Abbott Laboratories (NYSE: ABT) reported fourth-quarter earnings on Thursday, Jan. 26. Since then, Sanford C. Bernstein, Raymond James, Stifel Nicolaus, and Barclays have all raised their price targets on the healthcare conglomerate.
Abbott Laboratories ( NYSE:ABT ) Full Year 2022 Results Key Financial Results Revenue: US$43.7b (up 1.3% from FY 2021...